ECNP | Jotup

Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress

Retrieved on:

Friday, October 6, 2023

Congress, Central nervous system, C57BL/6J, Therapy, CORAL, European College of Neuropsychopharmacology, Psilocybin, CNS, Data, ECNP, CEST, Pharmaceutical industry

CORAL GABLES, Fla., Oct. 6, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will present three posters at the upcoming 36th European College of Neuropsychopharmacology (ECNP) Congress, taking place October 7-10, 2023, in Barcelona, Spain.

Key Points:

CORAL GABLES, Fla., Oct. 6, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that it will present three posters at the upcoming 36th European College of Neuropsychopharmacology (ECNP) Congress, taking place October 7-10, 2023, in Barcelona, Spain.
Details of the poster presentations are as follows:
Date & Time of Presentations: Sunday, October 8, 2023, 12:35-2:00pm CEST
Poster Title: Behavioral effects of a 14-day repeated treatment with psilocybin at a low non-psychedelic dose: a preliminary study in C57BL/6J mice
The posters will be available in the Data and Publications section of the Relmada website following the conclusion of the event.
For additional information about ECNP 2023, click here .

Newron to Present Three Posters on Its Clinical Program Evaluating Evenamide in the Treatment of Schizophrenia at the 36th European College of Neuropsychopharmacology Congress

Retrieved on:

Wednesday, October 4, 2023

Full results from all 161 patients who were randomized in study 014 and who completed six months of participation in study 015 will be presented.

Key Points:

Full results from all 161 patients who were randomized in study 014 and who completed six months of participation in study 015 will be presented.
Study 015 is an international, randomized, open-label, rater-blinded, phase II extension study of evenamide as an add-on therapy to an antipsychotic (excluding clozapine) in patients with moderate to severe TRS, not responding to their current antipsychotic medication.
Newron presented the data from all 161 patients at the six-week time point and data from the first 100 patients randomized in study 014 who completed one-year of participation in these studies at the 34th CINP World Congress of Neuropsychopharmacology and at the 2023 SIRS Annual Congress in May 2023.
The design of a potentially pivotal, international, randomized, double-blind, placebo-controlled, Phase III study aims to demonstrate the efficacy and tolerability of two doses (15 and 30 mg bid) of evenamide as an add-on treatment in TRS patients not benefiting from their current antipsychotic treatment will also be presented at the ECNP.

Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 36th European College of Neuropsychopharmacology (ECNP) Congress

Retrieved on:

Wednesday, October 4, 2023

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced it will be presenting new secondary efficacy, safety and tolerability, and pooled cognition data from its EMERGENT clinical program evaluating KarXT (xanomeline-trospium) in schizophrenia.

Key Points:

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced it will be presenting new secondary efficacy, safety and tolerability, and pooled cognition data from its EMERGENT clinical program evaluating KarXT (xanomeline-trospium) in schizophrenia.
The data will be presented at the upcoming 36th European College of Neuropsychopharmacology (ECNP) Congress, to be held October 7-10, 2023, in Barcelona, Spain.
“We’re eager to share these latest results, which further support KarXT’s differentiated safety and tolerability profile demonstrated in trials conducted to date and reinforce its potential to provide a broad range of clinically meaningful symptom improvements,” said Stephen Brannan, M.D., chief medical officer of Karuna Therapeutics.
“The complex challenges of schizophrenia underscore the urgent need for innovation.

ORYZON to Provide Corporate Progress Updates at Several Events in October

Retrieved on:

Monday, October 2, 2023

Oryzon will participate in the East-West Biopharma Summit, which will be held on October 2-4 in Kendall Square, Cambridge Mass.

Key Points:

Oryzon will participate in the East-West Biopharma Summit, which will be held on October 2-4 in Kendall Square, Cambridge Mass.
(USA), and virtually.
The company will provide a corporate update and will also hold one-on-one meetings with US and Chinese pharmaceutical companies and investors.
Click on link for more info about the ESMO 2023 congress

Cerevance Announces Presentation at the 36th European College of Neuropsychopharmacology Congress

Retrieved on:

Monday, October 2, 2023

Schizophrenia, European College of Neuropsychopharmacology, ECNP, Central nervous system, Therapy, Disease, Cerev Del, CNS, Pharmaceutical industry

BOSTON, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel precision therapeutics for central nervous system (CNS) diseases using the company’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform, today announced a poster presentation at the 36th European College of Neuropsychopharmacology Congress (ECNP), taking place in Barcelona, Spain from October 7 – 10, 2023.

Key Points:

BOSTON, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel precision therapeutics for central nervous system (CNS) diseases using the company’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) platform, today announced a poster presentation at the 36th European College of Neuropsychopharmacology Congress (ECNP), taking place in Barcelona, Spain from October 7 – 10, 2023.
Overview: CVN766 is a potent and selective orexin 1 receptor antagonist with a desirable pharmacokinetic profile for CNS indications.
In pre-clinical models, CVN766 demonstrated efficacy in models of schizophrenia across negative, positive, and cognitive symptomatology representing its potential as a novel therapeutic in this disease and other psychiatric conditions.

Newron Announces H1 2023 Results and Provides R&D Update

Retrieved on:

Friday, August 4, 2023

We have reported three striking sets of data from our evenamide development program for treatment-resistant schizophrenia (TRS), presented these results at international psychiatry scientific conferences, and published key results in a peer-reviewed journal.

Key Points:

We have reported three striking sets of data from our evenamide development program for treatment-resistant schizophrenia (TRS), presented these results at international psychiatry scientific conferences, and published key results in a peer-reviewed journal.
The exciting results triggered substantial interest from potential partners on future collaboration opportunities for the development of evenamide.”
In Q1 2023, Newron announced three exciting new sets of data evaluating evenamide as an add-on treatment for patients with TRS.
Study 008A is continuing to enroll patients in this indication, and results are expected by end of 2023/early in 2024.
Financial Summary (IFRS) H1 2023 and H1 2022:

EQS-News: Newron announces H1 2023 results and provides R&D update

Retrieved on:

Friday, August 4, 2023

We have reported three striking sets of data from our evenamide development program for treatment-resistant schizophrenia (TRS), presented these results at international psychiatry scientific conferences, and published key results in a peer-reviewed journal.

Key Points:

We have reported three striking sets of data from our evenamide development program for treatment-resistant schizophrenia (TRS), presented these results at international psychiatry scientific conferences, and published key results in a peer-reviewed journal.
Study 008A is continuing to enroll patients in this indication, and results are expected by end of 2023/early in 2024.
The results seen validate the rule of glutamate release inhibition in repairing disturbed neural connectivity in the TRS population.
Financial Summary (IFRS) H1 2023 and H1 2022:

Sage Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Highlights Pipeline and Business Progress

Retrieved on:

Thursday, February 16, 2023

Mental Health, Research, FDA, Neurology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Function (mathematics), NDA, PPD, Safety, Priority review, Proceedings of the Institution of Mechanical Engineers, Part B, Neuropsychiatry, Spectrum, Part, Learning, ECNP, D, Social, Memory, Commercialization, Zuranolone, Disorder, Shionogi, Depression, Grammatical mood, American Academy, GABAA, GABA, AD, Rehabilitation, Prescription Drug User Fee Act, HD, R, GABAA receptor positive allosteric modulator, DSM-IV codes, SG, PDUFA, PAM, Tremor, Patient, Incidence, Essential tremor, Webcast, NEST, Therapy, CIV, MDD, Huntington's disease, Epilepsy, Cognition, Woman, PD, MCI, NMDA, American Academy of Neurology, Medical Affairs Bureau, Plasma, Deficit spending, Conference, IND, Pharmaceutical industry, Medical device, Hunting, Design, Beauty salon, Boilermaker, Cryptocurrency, Biogen, Sage

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2022.

Key Points:

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2022.
In 2022, Sage and Biogen advanced commercialization plans for zuranolone through scientific exchange, permitted interactions with payers and disease state education in MDD and PPD.
Net Loss: Net loss was $147.1 million for the fourth quarter of 2022 compared to $124.7 million for the same period in 2021.
ET to review its fourth quarter and full year 2022 financial results and discuss recent corporate updates.

Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress

Retrieved on:

Tuesday, November 8, 2022

Mental Health, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Plasma, Achievement, Risk, MDD, Company, Private Securities Litigation Reform Act, AD, PD, NEST, U.S. Securities and Exchange Commission, Nasdaq, Solution, ECNP, Government budget balance, Congress, European College of Neuropsychopharmacology, D, Rehabilitation, Zuranolone, Neuropsychiatry, GABA, CIV, GABAA receptor positive allosteric modulator, Director, Grammatical mood, Tremor, IND, NDA, GABAA, NMDA, Epilepsy, Webcast, FDA, MCI, Patient, Essential tremor, Binary relation, Spectrum, PPD, SG, Research, Therapy, Safety, Food, Review, File, Disorder, PAM, Board, Neurology, Goal, Incidence, Depression, Security (finance), Fine chemical, Pharmaceutical industry, Medical device, Risk management, Beauty salon, Boilermaker, Management, Air cargo, Sage, Biogen, HD

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the third quarter ended September 30, 2022.

Key Points:

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the third quarter ended September 30, 2022.
We believe zuranolone, if approved, has the potential to deliver a new treatment option for patients, said Barry Greene, Chief Executive Officer at Sage Therapeutics.
During the third quarter, Sage announced key leadership changes:
Laura Gault, M.D., Ph.D., joined Sage as Chief Medical Officer.
ET to review its third quarter 2022 financial results and discuss recent corporate updates.

Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress

Retrieved on:

Monday, October 17, 2022

(Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today presented additional data from the Phase 3 SKYLARK Study of zuranolone in adult women with postpartum depression (PPD), at the 35th European College of Neuropsychopharmacology (ECNP) Congress, taking place October 15-18, 2022, in Vienna, Austria.

Key Points:

(Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today presented additional data from the Phase 3 SKYLARK Study of zuranolone in adult women with postpartum depression (PPD), at the 35th European College of Neuropsychopharmacology (ECNP) Congress, taking place October 15-18, 2022, in Vienna, Austria.
The study population was diverse, including approximately 22% Black or African American women and 38% identifying ethnically as Hispanic or Latina women.
The results of the SKYLARK Study are incredibly encouraging and show the potential positive impact zuranolone could have for women with PPD.
In the SKYLARK Study, zuranolone was generally well-tolerated, with a safety profile consistent with that observed in the clinical development program to date.